T. Sunaya

M. Momoeda, J. Kitawaki, T. Harada, 2022, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

Real-world outcomes of levonorgestrel-releasing intrauterine system for heavy menstrual bleeding or dysmenorrhea in Japanese patients: A prospective observational study (J-MIRAI).

M. Momoeda, J. Kitawaki, T. Harada, 2022, Contraception.

A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance

A. Gemma, H. Akaza, I. Hyodo, 2015, Japanese journal of clinical oncology.

Real-world outcomes of rivaroxaban treatment in patients with nonvalvular atrial fibrillation and worsening renal function.

T. Ikeda, S. Miyamoto, S. Ogawa, 2019, Journal of cardiology.

Real-world outcomes of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS).

T. Ikeda, S. Miyamoto, S. Ogawa, 2019, Journal of cardiology.

Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings

T. Ikeda, S. Miyamoto, S. Ogawa, 2019, Journal of Thrombosis and Thrombolysis.

Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study

S. Kaneko, J. Furuse, K. Okita, 2016, Journal of Gastroenterology.

Outcomes of sorafenib treatment of advanced renal cell carcinoma according to International Metastatic Renal Cell Carcinoma Data Consortium risk criteria: analysis of Japanese real-world data from postmarketing all-patient surveillance of sorafenib.

M. Oya, H. Azuma, T. Inamoto, 2022, Future oncology.

Real-World Data on Intravitreal Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion: 24-Month Outcomes

M. Shimura, T. Sunaya, M. Fukumatsu, 2022, Clinical ophthalmology.

Real-world use of sorafenib for advanced renal cell carcinoma patients with cardiovascular disease: nationwide survey in Japan

H. Akaza, M. Oya, K. Tatsugami, 2020, Expert review of anticancer therapy.

Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan.

T. Ikeda, S. Miyamoto, S. Ogawa, 2020, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

Safety Profile and Effectiveness of Rivaroxaban for Patients With Venous Thromboembolism in Japan　- Results From Post-Marketing Surveillance (XASSENT).

Takanori Hayasaki, K. Kawasugi, N. Yamada, 2023, Circulation Journal.

Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment

M. Oya, T. Imai, S. Kaneko, 2022, Cancer Chemotherapy and Pharmacology.

Safety and efficacy of regorafenib post-marketing surveillance (PMS) in Japanese patients with metastatic colorectal cancer (mCRC).

T. Nishida, K. Muro, K. Sugihara, 2017 .

Long-term surveillance provides real-world evidences of safety and effectiveness in intravitreal aflibercept treatment for age-related macular degeneration

K. Ohgami, T. Sunaya, Kazufumi Hirano, 2023, Scientific reports.

Real-world safety and effectiveness of rivaroxaban using Japan-specific dosage during long-term follow-up in patients with atrial fibrillation: XAPASS

T. Ikeda, S. Miyamoto, S. Ogawa, 2021, PloS one.

Safety and effectiveness of radium-223 dichloride (Ra-223) in patients with mCRPC in real-world setting: A Japanese post-marketing study (PMS).

N. Masumori, S. Kinuya, Y. Kakehi, 2020 .